Martin Shkreli @MartinShkreli · 03 Sep 2026
$RARE is very cheap. BMRN and other rare disease companies should explore buying the company. everyone and their brother with 3 months of med school/shkreli training knew this trial would fail
81 234Views
313Likes
11Reposts
31Replies
5Quotes
145Bookmarks
Is that a lot?
1.41×vs this author's median57 644 views is typical
50Percentile for this authorof 6 recent posts
3.71×vs 100K–1M median21 891 views is typical
12.78%Reachviews ÷ followers
0.44%Engagement rateof viewers reacted